Adagene (ADAG) News Today $2.10 +0.06 (+2.89%) Closing price 02/21/2025 03:50 PM EasternExtended Trading$2.08 -0.01 (-0.67%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Adagene Inc. (NASDAQ:ADAG) Short Interest UpdateAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 35,400 shares, a decline of 50.2% from the January 15th total of 71,100 shares. Currently, 0.1% of the company's stock are sold short. Based on an average trading volume of 93,700 shares, the days-to-cover ratio is presently 0.4 days.February 13, 2025 | marketbeat.comAdagene (NASDAQ:ADAG) Rating Lowered to Equal Weight at Morgan StanleyMorgan Stanley lowered Adagene from an "overweight" rating to an "equal weight" rating in a research note on Friday.January 31, 2025 | marketbeat.comMorgan Stanley downgrades Adagene (ADAG) to a HoldJanuary 31, 2025 | markets.businessinsider.comAdagene downgraded to Equal Weight from Overweight at Morgan StanleyJanuary 31, 2025 | markets.businessinsider.comAdagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 79,600 shares, a growth of 21.9% from the December 31st total of 65,300 shares. Based on an average daily trading volume, of 60,400 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.2% of the company's shares are sold short.January 31, 2025 | marketbeat.comCD47 Inhibitor Drug Clinical Trials Market Opportunity Outlook 2028, Competitive Analysis of Adagene, ALX, ImmuneOncia, ImmuneOnco, Light Chain Bioscience, Phanes, and Virtuoso,January 29, 2025 | globenewswire.comFY2024 Earnings Forecast for Adagene Issued By HC WainwrightAdagene Inc. (NASDAQ:ADAG - Free Report) - Research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Adagene in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst A. He now anticipates that the company will earn ($January 29, 2025 | marketbeat.comFY2029 Earnings Estimate for Adagene Issued By HC WainwrightAdagene Inc. (NASDAQ:ADAG - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Adagene in a research note issued to investors on Monday, January 27th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.56) perJanuary 28, 2025 | marketbeat.comAdagene announces updated data from Phase 1b/2 study of muzastotug, keytrudaJanuary 27, 2025 | markets.businessinsider.comAdagene price target raised to $8 from $5 at H.C. WainwrightJanuary 27, 2025 | msn.comAdagene’s ADG126: Promising Efficacy and Safety Profile Justifies Buy RatingJanuary 27, 2025 | markets.businessinsider.comH.C. Wainwright lifts Adagene stock target to $8 on ASCO dataJanuary 27, 2025 | msn.comAdagene reports positive colorectal cancer trial resultsJanuary 27, 2025 | msn.comHC Wainwright Forecasts Strong Price Appreciation for Adagene (NASDAQ:ADAG) StockHC Wainwright upped their price target on Adagene from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Monday.January 27, 2025 | marketbeat.comAdagene Reports Promising Results in Colorectal Cancer StudyJanuary 27, 2025 | tipranks.comAdagene to present new ADG126 clinical data at ASCO-GIJanuary 21, 2025 | msn.comAdagene Inc. to Present Updated Clinical Data for ADG126 in MSS Colorectal Cancer at ASCO Gastrointestinal Cancers SymposiumJanuary 21, 2025 | quiverquant.comAdagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers SymposiumJanuary 21, 2025 | globenewswire.comAdagene to host virtual KOL event to discuss SAFEbodyADG126January 16, 2025 | markets.businessinsider.comNovember 2024's Top Picks: Penny Stocks On US ExchangesNovember 29, 2024 | uk.finance.yahoo.comAdagene Inc. (NASDAQ:ADAG) Sees Large Decrease in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 12,300 shares, a decline of 42.5% from the October 15th total of 21,400 shares. Based on an average daily trading volume, of 88,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are short sold.November 13, 2024 | marketbeat.comAdagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingNovember 7, 2024 | globenewswire.comCoya stock tumbles 23% on mixed results from Alzheimer's studyOctober 29, 2024 | msn.comAdagene Inc. (NASDAQ:ADAG) Short Interest Down 30.7% in OctoberAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 21,400 shares, a decrease of 30.7% from the September 30th total of 30,900 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 75,400 shares, the short-interest ratio is presently 0.3 days.October 27, 2024 | marketbeat.comAdagene And 2 Other US Penny Stocks To ConsiderOctober 22, 2024 | finance.yahoo.comAdagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingOctober 9, 2024 | globenewswire.comAdagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG)Adagene Inc. (NASDAQ:ADAG - Free Report) - Research analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Adagene in a note issued to investors on Wednesday, September 18th. HC Wainwright analyst A. He now expects that the company will post earnings per share of ($0.78) fSeptember 20, 2024 | marketbeat.comBuy Rating Affirmed on Adagene: Promising ADG126 Clinical Data and Market UnderappreciationSeptember 19, 2024 | markets.businessinsider.comAdagene (NASDAQ:ADAG) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of Adagene in a research note on Wednesday.September 18, 2024 | marketbeat.comAdagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)September 16, 2024 | globenewswire.comCD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027September 12, 2024 | finance.yahoo.comAdagene to Participate in Investor Conferences in SeptemberAugust 29, 2024 | finance.yahoo.comAdagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in AugustAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 13,000 shares, a growth of 170.8% from the July 31st total of 4,800 shares. Currently, 0.0% of the company's stock are sold short. Based on an average trading volume of 49,500 shares, the short-interest ratio is presently 0.3 days.August 28, 2024 | marketbeat.comMorgan Stanley Reaffirms Their Buy Rating on Adagene (ADAG)August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Poseida Therapeutics Amidst Promising Clinical and Financial UpdatesAugust 6, 2024 | markets.businessinsider.comBuy Rating on Adagene: Market Advantage and Promising Clinical Trials Fuel Growth PotentialJuly 23, 2024 | markets.businessinsider.comAdagene Inc ADR ADAGJuly 19, 2024 | morningstar.comAdagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in JuneAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 19,700 shares, a growth of 45.9% from the June 15th total of 13,500 shares. Based on an average trading volume of 31,900 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.1% of the company's stock are short sold.July 13, 2024 | marketbeat.comAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in SeptemberJuly 12, 2024 | globenewswire.comAdagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 13,500 shares, a growth of 400.0% from the May 31st total of 2,700 shares. Based on an average daily volume of 32,700 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the company's stock are short sold.June 27, 2024 | marketbeat.comAdagene Inc. (NASDAQ:ADAG) Short Interest Down 75.7% in MayAdagene Inc. (NASDAQ:ADAG - Get Free Report) saw a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 2,700 shares, a decline of 75.7% from the May 15th total of 11,100 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 32,000 shares, the days-to-cover ratio is presently 0.1 days.June 12, 2024 | marketbeat.comAdagene Inc. (NASDAQ:ADAG) Sees Significant Decrease in Short InterestAdagene Inc. (NASDAQ:ADAG - Get Free Report) was the target of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 11,100 shares, a drop of 26.5% from the April 30th total of 15,100 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 34,900 shares, the short-interest ratio is presently 0.3 days.May 30, 2024 | marketbeat.comAdagene to Present at Investor Conferences in JuneMay 22, 2024 | globenewswire.comWuXi AppTec Co. Ltd. Takes Position in Adagene Inc. (NASDAQ:ADAG)WuXi AppTec Co. Ltd. acquired a new stake in Adagene Inc. (NASDAQ:ADAG - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,225,696 shares of the company's stock, vMay 8, 2024 | marketbeat.comMorgan Stanley lifts Adagene stock target on positive dataApril 10, 2024 | investing.comAdagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 31, 2024 | finanznachrichten.deAdagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | globenewswire.comAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardMarch 7, 2024 | globenewswire.comAdagene to Present at the Leerink Partners Global Biopharma Conference 2024February 27, 2024 | globenewswire.comAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)February 9, 2024 | finance.yahoo.com Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAG Media Mentions By Week ADAG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADAG News Sentiment▼0.000.60▲Average Medical News Sentiment ADAG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADAG Articles This Week▼00▲ADAG Articles Average Week Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AQST News Today GOSS News Today CADL News Today ATYR News Today IMMP News Today OLMA News Today KRRO News Today NMRA News Today YMAB News Today KOD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADAG) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
